Seqalis

Executive Summary

Seqalis is a Belgian contract research organization (CRO) founded in 2018 and headquartered in Leuven, specializing in molecular biology, cytogenomics, and anatomical pathology services. The company positions itself as a scientific partner to healthcare innovators, offering high-quality DNA/RNA sequencing, PCR, T cell repertoire sequencing, and biobanking. With a focus on cutting-edge laboratory testing and analysis, Seqalis supports drug development, diagnostics, and personalized medicine initiatives. Its services cater to biotech and pharmaceutical clients seeking robust genomic and molecular insights, leveraging advanced technologies to ensure accuracy and reproducibility. As a private company in Phase 2 of its development, Seqalis is well-positioned to capture demand in the rapidly expanding European CRO market, particularly in the genomics segment. The company’s expertise in NGS and cytogenomics, combined with its strategic location in a prominent life sciences hub, enables it to offer competitive turnaround times and customizable workflows. While the CRO space is fragmented and competitive, Seqalis differentiates through specialization in rare disease and oncology-related assays. The firm’s growth trajectory hinges on expanding its service portfolio, securing partnerships, and achieving regulatory accreditations. With increasing outsourcing trends in pharma R&D, Seqalis has the potential to scale its operations and capture a larger share of the contract research market, though it must navigate capital constraints and regulatory challenges typical of early-stage service providers.

Upcoming Catalysts (preview)

• Q4 2026Launch of Liquid Biopsy Testing Service65% success
• Q3 2026Strategic Partnership with a Major Pharmaceutical Company for Clinical Trial Support45% success
• Q2 2026Achievement of ISO 15189 Accreditation80% success